CA
NZ
UK
AU
IND
US
LifeStance Health Group, Inc. (NASDAQ: LFST) disclosed a sudden change to its board composition on July 2, 2026. The filing noted the immediate exit of one director and the addition of three new members, marking a notable shift in governance structure.
Prime Medicine resolves key legal challenge Prime Medicine (NASDAQ: PRME) has overcome a significant legal obstacle in its development pipeline after an arbitration tribunal ruled in its favor against Beam Therapeutics. The decision confirms the company’s rights to advance PM647, its experimental treatment for …
VSEE HEALTH, INC. Has announced new financing agreements with institutional investors, marking a significant development in the company's growth strategy. This financing move is expected to boost the company's financial position in the healthcare sector.
GMR Solutions Inc. (NYSE: GMRS) has bolstered its board with two new independent directors, tapping executives with decades of healthcare experience. The appointments of Dr. Amar Desai and Ellen Zane took effect July 1, 2026, as disclosed in a regulatory filing.
Oncology Institute entered into a loan agreement with OrbiMed Opportunities (CA) V LLC serving as the lead lender. The facility, aggregating a principal amount of $75 million, was drawn in full at closing, delivering immediate capital to support the company’s debt restructuring strategy. The …
Seres Therapeutics, Inc. (NASDAQ: MCRB) announced that its SER-155 program generated encouraging early data in a trial targeting immune‑related colitis. The company released a corporate presentation alongside the results, underscoring the therapeutic potential of a microbiome‑based approach that avoids systemic steroids.
ARS Pharmaceuticals undergoes a leadership transition, marking a new chapter for the biotech firm. The company has announced a shift in its executive team, signaling potential strategic adjustments ahead.
CalciMedica Inc. (NASDAQ: CALC) has expanded its board of directors to eight members. This move is part of the company's efforts to strengthen its governance and leadership in the healthcare sector. The expansion is expected to bring new perspectives and expertise to the board.
Keenova Therapeutics plc disclosed on July 8, 2026 that its Phase 3 investigation of XIAFLEX for plantar fibromatosis met the trial’s primary and key secondary objectives. The announcement follows a regulatory filing that underscores both efficacy signals and a tolerability record consistent with existing …
Ovid Therapeutics (NASDAQ: OVID) announced a change in its financial leadership, naming Charles Carter as its new Chief Financial Officer. The move follows the departure of Jeffrey Rona, who held multiple executive roles, including principal financial and accounting officer. His prior experience includes CFO …
Please wait processing your request...